Evaluation of safety and efficacy of topical Sucranica cream to treat fresh wounds

Evaluation of safety and efficacy of topical Sucranica cream to treat fresh wounds after skin lesions removal by Radio Frequency (RF) Surgical

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190210042676N37

Enrollment

Registered

2024-12-31

Start date

2025-01-04

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin lesions. Changes in skin texture

Interventions

Intervention 1: Intervention group:After the RF procedure, will receive topical Lafarrerr Sucranica cream, made by Dr. Kamkar Laboratory, commissioned by Fartak Lotus Chemical Industries, containing s

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 18-65 years old men and women People who treated a benign skin lesion (skin tassel, wart, sebaceous hyperplasia, seboric keratosis) in the facial areas by Surgical RF method. wounds in the range of 1-100 square millimeters

Exclusion criteria

Exclusion criteria: Use of anticoagulant, phototoxic, photoallergic, steroid and non-steroid anti-inflammatory drugs in the last three months. History of malignant lesion Pregnancy and lactating

Design outcomes

Primary

Measure	Time frame
Skin erythema changes. Timepoint: Before intervention and 2 weeks after using. Method of measurement: Mexameter.	—

Secondary

Measure	Time frame
Skin melanin content changes. Timepoint: Before intervention and 2 weeks after using. Method of measurement: Mexameter.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAniseh Samadi

Tehran University of Medical Sciences

aniseh_samadi@yahoo.com+98 21 8896 0880

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026